Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases.
Bisphosphonates (BP) are nonhormonal medications used in the treatment of various bone malignancies and metabolic conditions. Since 2003, there have appeared a significant and growing number of articles in the worldwide medical and dental literature describing the complication of an osteonecrosis of the jaws associated with the intravenous and, most recently, the oral form of BP medication that has been refractory to any definitive form of treatment. The authors have successfully managed 2 patients taking the oral form of BP with adjunctive treatment using platelet-rich plasma (PRP), and in one case with hyperbaric oxygen (HBO). We were able to obtain complete remission in each case, which is defined as resolution of pain and complete closure of exposed bone in the jaws. The purpose of this report is to describe a treatment protocol and the rationale for using PRP and HBO to obtain complete remission of this new pathologic condition.
Lee
Cameron Y S
CY
CLee555294@aol.com
David
Teresa
T
Nishime
Michael
M
D000196:Actinomycosis / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006931:Hyperbaric Oxygenation; D007571:Jaw Diseases / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D053657:Platelet-Rich Plasma
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019386:Alendronate